Cargando…

Prediction of Fracture Risk From Early‐Stage Bone Markers in Patients With Osteoporosis Treated With Once‐Yearly Administered Zoledronic Acid

The prevention of fractures is the ultimate goal of osteoporosis treatments. To achieve this objective, developing a method to predict fracture risk in the early stage of osteoporosis treatment would be clinically useful. This study aimed to develop a mathematical model quantifying the long‐term fra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kasai, Hidefumi, Mori, Yoko, Ose, Atsushi, Shiraki, Masataka, Tanigawara, Yusuke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048549/ https://www.ncbi.nlm.nih.gov/pubmed/33135182 http://dx.doi.org/10.1002/jcph.1774

Ejemplares similares

Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker
por: Mori, Y., et al.
Publicado: (2018)

1566. Population Pharmacokinetics of Voriconazole: Serum Albumin Status as a Novel Marker of Clearance and Dosage Optimization
por: Chantharit, Prawat, et al.
Publicado: (2019)

Once-yearly zoledronic acid in hip fracture prevention
por: Demontiero, Oddom, et al.
Publicado: (2009)

Treatment of postmenopausal osteoporosis, patient perspectives – focus on once yearly zoledronic acid
por: Carmona, Raj, et al.
Publicado: (2009)

Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study)
por: Nakamura, T., et al.
Publicado: (2016)

New simulation model for bone formation markers in osteoporosis patients treated with once-weekly teriparatide
por: Tanaka, Sakae, et al.
Publicado: (2014)

Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan
por: Moriwaki, K., et al.
Publicado: (2017)

Pharmacodynamic analysis of hypertension caused by lenvatinib using real‐world postmarketing surveillance data
por: Otani, Yuki, et al.
Publicado: (2021)

Pharmacometric analysis of seasonal influenza epidemics and the effect of vaccination using sentinel surveillance data
por: Otani, Yuki, et al.
Publicado: (2021)

Treatment responses with once-weekly teriparatide therapy for osteoporosis
por: Shiraki, M., et al.
Publicado: (2016)

Effects of once-yearly zoledronic acid on bone density and incident vertebral fractures in nonmetastatic castration-sensitive prostate cancer patients with osteoporosis
por: Watanabe, Daisuke, et al.
Publicado: (2021)

Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women
por: Lambrinoudaki, Irene, et al.
Publicado: (2008)

Oral Therapeutics Post Menopausal Osteoporosis
por: Schroeder, Ryan J, et al.
Publicado: (2023)

Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma
por: Veltman, J D, et al.
Publicado: (2010)

Profile of changes in bone turnover markers during once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis
por: Sugimoto, T., et al.
Publicado: (2013)

Safety and effectiveness of once-yearly zoledronic acid in Japanese osteoporosis patients: three-year post-marketing surveillance
por: Takada, Junichi, et al.
Publicado: (2023)

Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro
por: Tassone, P, et al.
Publicado: (2003)

Acute Phase Reactions After Intravenous Infusion of Zoledronic Acid in Japanese Patients with Osteoporosis: Sub-analyses of the Phase III ZONE Study
por: Shiraki, Masataka, et al.
Publicado: (2021)

Treatment of osteoporosis with annual iv zoledronic acid: effects on hip fracture
por: Chapurlat, Roland D
Publicado: (2009)

The bisphosphonate zoledronic acid impairs membrane localisation and induces cytochrome c release in breast cancer cells
por: Senaratne, S G, et al.
Publicado: (2002)

Once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis: reply to T. Kawada
por: Sugimoto, T., et al.
Publicado: (2014)

24-Month Open-Label Teriparatide Once-Weekly Efficacy Research Trial Examining Bone Mineral Density in Subjects with Primary Osteoporosis and High Fracture Risk
por: Sugimoto, Toshitsugu, et al.
Publicado: (2017)

Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma
por: Horie, N, et al.
Publicado: (2007)

Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer
por: Duivenvoorden, W C M, et al.
Publicado: (2007)

New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects
por: Denoyelle, C, et al.
Publicado: (2003)

Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction
por: Neville-Webbe, H L, et al.
Publicado: (2010)

Role of zoledronic acid in the prevention and treatment of osteoporosis
por: Räkel, Agnès, et al.
Publicado: (2011)

Zoledronic acid infusion for prevention and treatment of osteoporosis
por: Sunyecz, John A
Publicado: (2010)

Reduction effect of oral pravastatin on the acute phase response to intravenous zoledronic acid: protocol for a real-world prospective, placebo-controlled trial
por: Liu, Qi, et al.
Publicado: (2022)

Management of osteoporosis in the aging male: Focus on zoledronic acid
por: Piper, Paul K, et al.
Publicado: (2009)

Six monthly intravenous zoledronic acid in childhood osteoporosis
por: Munns, CF, et al.
Publicado: (2013)

Clinical effect of Zoledronic Acid in the treatment of Senile Osteoporosis
por: Kong, Li, et al.
Publicado: (2020)

How zoledronic acid improves osteoporosis by acting on osteoclasts
por: Wang, Biao, et al.
Publicado: (2022)

Eldecalcitol reduces the risk of severe vertebral fractures and improves the health-related quality of life in patients with osteoporosis
por: Hagino, Hiroshi, et al.
Publicado: (2012)

Once-monthly risedronate for postmenopausal osteoporosis
por: Casadei, Kristina, et al.
Publicado: (2010)

Systemically administered PEDF against primary and secondary tumours in a clinically relevant osteosarcoma model
por: Broadhead, M L, et al.
Publicado: (2011)

Effect of dose administration aids on adherence to self-administered medications: a systematic review protocol
por: Chaudhri, Kanika, et al.
Publicado: (2019)

Efficacy of Intravenously Administered Gepotidacin in Cynomolgus Macaques following a Francisella tularensis Inhalational Challenge
por: Jakielaszek, Charles, et al.
Publicado: (2023)

In vitro and in vivo effects of easily administered, low-toxic retinoid and phenylacetate compounds on human neuroblastoma cells
por: Sidell, N, et al.
Publicado: (2003)

Pharmacodynamic analysis of eribulin safety in breast cancer patients using real‐world postmarketing surveillance data
por: Kawamura, Takahisa, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ferh365cernqmkm75ul40oviha